Dimethyl fumarate (DMF), an FDA−approved NRF2 agonist for multiple sclerosis, indirectly inhibits NF−κB and has demonstrated antifibrotic effects by restoring redox homeostasis in aged IPF models (161). This evidence concerns the gene NFKB1 and idiopathic pulmonary fibrosis.